1.Fava, M, Rush, AJ, Alpert, JE, et al.Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342–351.
2.Gaspersz, R, Nawijn, L, Lamers, F, Penninx, B. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17–25.
3.Fava, M, Alpert, JE, Carmin, CN, et al.Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):1299–1308.
4.Braund, TA, Palmer, DM, Williams, LM, Harris, AWF. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report. Psychol Med. 2019 Apr 26:1–11. doi:10.1017/S0033291719000941
5.Braund, TA, Palmer, DM, Williams, LM, Harris, AW. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: an iSPOT-D report. Aust N Z J Psychiatry. 2019;58(8):782–793.
6.Wiethoff, K, Bauer, M, Baghai, TC, et al.Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J Clin Psychiatry. 2010;71(8):1047–1054.
7.Murrough, JW, Iosifescu, DV, Chang, LC, et al.Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142.
8.Su, TP, Chen, MH, Li, CT, et al.Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42(13):2482–2492.
9.Salloum, NC, Fava, M, Freeman, MP, et al.Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression Anxiety. 2019;36(3):235–243.
10.Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, et al.Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932–e938.
11.Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, Richards, EM, Zarate, CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord . 2015;17(4):438–443.
12.Li, CT, Chen, MH, Lin, WC, et al.The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp. 2016;37(3):1080–1090.
13.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
14.Montgomery, SA, Rani, SJ, McAuley, R, Roy, D, Montgomery, DB. The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatr Scand Suppl. 1981;290:219–224.
15.Cleary, P, Guy, W. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res. 1977;(1):115–120.
16.Jakubovski, E, Bloch, MH. Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry. 2014;75(7):738–747.
17.Clarke, E, Clarke, P, Gill, S, Paterson, T, Hahn, L, Galletly, C. Efficacy of repetitive transcranial magnetic stimulation in the treatment of depression with comorbid anxiety disorders. J Affect Disord. 2019;252:435–439.
18.Su, TP, Huang, CC, Wei, IH. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. J Clin Psychiatry. 2005;66(7):930–937.
19.Glue, P, Medlicott, NJ, Harland, S, et al.Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):1302–1305.
20.Taylor, JH, Landeros-Weisenberger, A, Coughlin, C, et al.Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2018;43(2):325–333.
21.Feder, A, Parides, MK, Murrough, JW, et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA psychiatry. 2014;71(6):681–688.
22.Frye, MA, Blier, P, Tye, SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–336.